SCHEMBL13329375

SCHEMBL13329375

CC(C)(C)OC(=O)N1CCc2nc(O)n(C(c3ccccc3)c3ccccc3)c(=O)c2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.42
TNKS2 Q9H2K2 1/20 0.42
PARP2 Q9UGN5 1/20 0.42
MAPT P10636 2/20 0.41
PDE10A Q9Y233 1/20 0.41
ESR2 Q92731 1/20 0.41
P2RX3 P56373 2/20 0.40
F12 P00748 1/20 0.40
MTHFD2 P13995 1/20 0.39
C5AR1 P21730 1/20 0.39
PDK4 Q16654 1/20 0.38
GRAMD1A Q96CP6 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
GLS O94925 1/20 0.38
MAPK1 P28482 1/20 0.38
NR1H2 P55055 1/20 0.38
MTOR P42345 1/20 0.38
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328836 0.90 MAPT (0.43) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL13329616 0.89 MAPT (0.43) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL13328851 0.89 F12 (0.43) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL13329615 0.87 PARP1 (0.40) PARP1TNKS2PARP2MAPTPDE10A
SCHEMBL13328818 0.85 PRLHR (0.42) MAPT
SCHEMBL13250063 0.83 PARP1 (0.40) PARP1TNKS2PARP2MAPTP2RX3
SCHEMBL13250072 0.82 PARP1 (0.44) PARP1TNKS2PARP2ESR2P2RX3
SCHEMBL13249769 0.82 PARP1 (0.48) PARP1TNKS2PARP2MAPTESR2
SCHEMBL13249776 0.81 PARP1 (0.47) PARP1TNKS2PARP2MAPTESR2
SCHEMBL13250046 0.81 PARP1 (0.47) PARP1TNKS2PARP2MAPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
WO-2008130584-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF SCHERING CORPORATION (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 PARP1 971/4885TNKS2 1527/4885PARP2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.